Regeneron Pharmaceuticals (NASDAQ:REGN) Given “Market Perform” Rating at Leerink Partners

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “market perform” rating restated by equities researchers at Leerink Partners in a report issued on Tuesday, Benzinga reports. They currently have a $1,077.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $1,175.00. Leerink Partners’ price objective would suggest a potential downside of 1.37% from the stock’s current price.

Several other brokerages have also recently issued reports on REGN. JPMorgan Chase & Co. boosted their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Royal Bank of Canada reiterated an “outperform” rating and set a $1,282.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 17th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Wells Fargo & Company reissued an “overweight” rating and set a $1,200.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday. Finally, Truist Financial restated a “buy” rating and issued a $1,200.00 price target (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,109.67.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $1,091.98 on Tuesday. Regeneron Pharmaceuticals has a one year low of $769.19 and a one year high of $1,211.20. The stock has a market capitalization of $120.32 billion, a price-to-earnings ratio of 32.26, a PEG ratio of 3.93 and a beta of 0.12. The company has a 50-day simple moving average of $1,131.94 and a 200-day simple moving average of $1,033.46. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the prior year, the business earned $8.79 EPS. The firm’s revenue was up 12.3% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals will post 37.8 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the sale, the executive vice president now directly owns 37,937 shares of the company’s stock, valued at approximately $41,311,496.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The disclosure for this sale can be found here. Insiders sold a total of 9,270 shares of company stock valued at $10,695,833 in the last ninety days. Corporate insiders own 7.48% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Greater Midwest Financial Group LLC lifted its position in Regeneron Pharmaceuticals by 8.8% during the second quarter. Greater Midwest Financial Group LLC now owns 2,502 shares of the biopharmaceutical company’s stock worth $2,894,000 after buying an additional 203 shares during the period. Centaurus Financial Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $118,000. Prio Wealth Limited Partnership acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $210,000. Sanctuary Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $47,611,000. Finally, Kestra Investment Management LLC purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $437,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.